Talk:TRIUMPH trial programme

Discussion page·2 threads·no archives

Tagged {{update}} pending phase 3 publication.

This is the discussion page for the article TRIUMPH trial programme. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.

Quoting phase 2 figuresResolved

Every figure in this article is from phase 2 and that must be unmissable. The closing section now says it in as many words. — TriumphThad (talk) 09:55, 25 March 2026 (UTC)

And the point that phase 2 point estimates are the least reliable part of a phase 2 result is stated as a general property, which is fairer than singling out this trial. ✓ Done — PreregPriya (talk) 13:30, 25 March 2026 (UTC)

Resolved. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.

Heart-rate signal

Calling this the signal most likely to determine risk–benefit is a judgement. Is it one the article should make? — SafetySignalSid (talk) 10:40, 8 June 2026 (UTC)

It is a judgement, and I have grounded it in three stated properties — dose-related, mechanistically expected, cumulative — so a reader can disagree with the reasoning rather than only the conclusion. — RetatrutideRuben (talk) 14:15, 8 June 2026 (UTC)

This page was last edited on 8 June 2026, by RetatrutideRuben. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).